Moderna (NASDAQ: MRNA) may finally have the catalyst investors have been waiting for beyond COVID. A successful Phase 3 melanoma study strengthens the case for personalized mRNA cancer treatment, but the stock's huge rerating now leaves one question dominant: Can this become a durable oncology franchise, or has the market moved faster than the evidence? Stock prices used were the market prices of Sept. 1, 2026. The video was published on Sept. 21, 2026. Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.